RGA

ANALYST NOTE: RGA (Reinsurance Group of America, Incorporated) Date: 2026-06-20 Current Price: $210.54

1. Structural Readiness

State: Context-Only Conservative Entry: Not yet defined (awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: N/A (Current price is not a confirmed entry signal for a forming coil) Breakout Level: Not yet defined Current Price: $210.54 Extension: N/A (Price is within the forming range, not extended above a breakout) ATR Current: 2.3% (Sub-threshold volatility)

Analysis of Setup:

• Volatility Context: The current ATR of 2.3% is sub-threshold (below the 4% historical sweet spot). This suggests the stock is currently in a low-volatility consolidation phase, typical of a forming coil, but lacks the immediate momentum signature of a high-quality breakout setup until volatility expands.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Thesis: None named at this date.

Analysis: There is no named macro or secular thesis attached to RGA in the current evidence set for June 20, 2026. This is a TACTICAL setup. The investment case must be judged strictly on the quality of the structural setup (the forming coil) and the underlying business fundamentals as reported by management. We are not assigning a "long-term secular growth" label here; we are evaluating the company based on its current execution, capital deployment, and the technical readiness of the price structure. The conviction must derive from the alignment of the forming technical structure with the strong operational data provided in the Q1 2026 earnings.

3. Business Analysis

Company Overview: Reinsurance Group of America, Incorporated (RGA) is a leading global provider of life reinsurance and financial solutions. As of March 31, 2026, the company manages $4.3 trillion of life reinsurance in force and holds $164.1 billion in assets.

Business Model & Segments: The company operates through two primary segments:

• Traditional Reinsurance: Involves reinsuring life and health policies (individual and group) with premiums earned over 10 to 30 years.
• Financial Solutions: Includes asset-intensive reinsurance, longevity reinsurance, pension risk transfer (PRT), and capital solutions.

Operational Highlights (Source: Q1 2026 Earnings & Filings):

• Capital Deployment: Management deployed $338 million into in-force transactions during the quarter ended March 31, 2026.
• Capital Position: The company ended the quarter with estimated excess capital of $2.4 billion and estimated deployable capital for the next twelve months of $2.9 billion.
• Growth Metrics: New business production (face amount) reached $150.6 billion in 2026, up from $131.7 billion in 2025. Consolidated assumed life reinsurance in force grew to $4.3 trillion from $4.0 trillion a year prior.
• Strategic Transactions: The company completed a significant transaction with Equitable Holdings on July 31, 2025 (reported in Q1 2026), assuming a 75% quota share of Equitable's in-force individual life liabilities (approx. $12 billion in liabilities). This contributed to the increase in adjusted operating income.
• Geographic Performance: Asia Pacific delivered another strong quarter, driven by growth in Japan and Korea, with notable transactions in both asset and biometric risk.
• Claims Experience: Since the beginning of 2023, economic claims experience has been favorable by $343 million.
• Investment Assumptions: Management is assuming a 7% variable investment income return for the current period, noting this is below their longer-term expectations of 10-12% due to a muted real estate sales environment.

4. Archetype and Conviction

Archetype: Quality Compounder Fit Analysis: RGA fits the Quality Compounder archetype. The evidence supports a business model characterized by:

• Scale and Moat: $4.3 trillion in force and global reach.
• Capital Efficiency: Strong excess capital generation ($2.4B) allowing for selective deployment ($338M in one quarter).
• Operational Leverage: Favorable claims experience ($343M since 2023) and growing new business production ($150.6B in 2026).
• Strategic Execution: Successful integration of the Equitable Holdings transaction and strong execution in Asia.

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. The Q1 2026 data is robust, with specific figures on capital, in-force growth, and transactional success.
• Rerating Potential: Moderate. The company is executing well, but the "sub-threshold" volatility suggests the market is currently in a wait-and-see mode regarding the 7% investment return assumption and the long-term impact of the Equitable transaction.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Breakout Confirmation: A daily close above the established coil resistance level with expanding volume.
• Investment Return Reversion: Management guidance indicating a return to the 10-12% variable investment income range, signaling the end of the muted real estate environment.
• Capital Deployment Acceleration: Deployment of capital exceeding the $2.9B next-12-months estimate, indicating high-conviction opportunities.

What Would Invalidate the Case:

• Fundamental Deterioration: A significant widening of the claims experience gap (e.g., a shift from favorable to unfavorable claims) or a failure to deploy capital due to a lack of attractive opportunities.
• Investment Income Shock: A material reduction in the assumed investment return below the 7% level, or a failure to recognize income from real estate sales as expected.

Gaps in Evidence:

• Breakout Level: The specific resistance level to watch for a confirmed breakout is not defined in the text.
• Forward Guidance Nuance: While 2026 production is known, specific guidance for 2027 or beyond regarding the "muted real estate" environment is not detailed in the provided excerpts.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: $2.4B excess capital and $2.9B deployable capital; $150.6B new business production in 2026; Favorable claims experience of $343M since 2023. Sizing hint: Position size should be conservative until the breakout fires; current setup is a partial signal. Expected path: Management expects continued capital deployment and growth in Asia; structural implication is a potential re-rating if investment returns normalize to 10-12%. Expected horizon: 3 to 6 months for the forming coil to resolve into a confirmed breakout or invalidation.